Peptide Schedule
Teduglutide (Gattex/Revestive)33 residuesHGDGSFSDEMNTILDNLAARDFINWLIQTKITDEach bubble = one amino acid. Size = residue mass. Color = chemical class.

Teduglutide (Gattex/Revestive) Dosage Calculator

Healing & RecoveryInjectionFDA Approved~2 hours half-life

Teduglutide (brand names Gattex in the US, Revestive in Europe) is an FDA-approved recombinant analog of glucagon-like peptide-2 (GLP-2) manufactured by Takeda for the treatment of adults and pediatric patients (1 year and older) with short bowel syndrome (SBS) who are dependent on parenteral support.

FDA-approved for short bowel syndrome with proven reduction in parenteral support dependencePromotes intestinal mucosal adaptation — increases villus height, crypt depth, and absorptive surface areaEnhances intestinal fluid and nutrient absorption capacityRestores more normal gastric emptying and intestinal secretion

2,500mcg · Daily

100500
0.0 units
100 units (1mL)
Concentration
0
mcg/mL
Draw Volume
< 0.001
mL
Syringe Units
< 0.1
units
Doses / Vial
0
doses

Summary: Add 0mL BAC water to your 5mg vial. Draw to < 0.1 units on a U-100 syringe for a 2,500mcg dose. This vial will last 0 doses.

Cycle Planner

Subcutaneous. Typical beginner frequency: daily.

Teduglutide (Gattex/Revestive) Pharmacokinetics

Pharmacokinetics — Active Dose Over Time

t½ = ~2 hours (1.3h in SBS patients; range 0.9-3h depending on body weight)
50%25%12.5%100%75%50%25%0%02h4h6h8h10hTime after injectionDose remaining
After 1 half-life (2h): 50% remainsAfter 2 half-lives (4h): 25% remainsAfter 3 half-lives (6h): 12.5% remains
At a 3.5mg dose: 50% = 1.8mg remaining after 2h. Recommended frequency: Daily.

Disclaimer: This curve is a simplified first-order exponential decay model. Actual pharmacokinetics vary based on injection site, individual metabolism, body composition, and other factors. Half-life values are approximate and based on available preclinical and clinical literature. Many research peptides lack formal human pharmacokinetic studies. This is for educational purposes only — not medical advice.

Teduglutide (Gattex/Revestive) Dosing Protocol

LevelDose / InjectionFrequency
Beginner2,500mcgDaily
Moderate3,500mcgDaily
Aggressive5mgDaily

Note: FDA-approved GLP-2 analog for short bowel syndrome-associated intestinal failure. Weight-based dosing at 0.05 mg/kg/day SC. Supplied as 5mg lyophilized powder; reconstitute with 0.5mL sterile water for injection (10 mg/mL). Reduce dose to 0.025 mg/kg/day in patients with moderate-to-severe renal impairment (eGFR <60). Colonoscopy required within 6 months before starting treatment and at least every 5 years thereafter.

About Teduglutide (Gattex/Revestive)

Teduglutide (brand names Gattex in the US, Revestive in Europe) is an FDA-approved recombinant analog of glucagon-like peptide-2 (GLP-2) manufactured by Takeda for the treatment of adults and pediatric patients (1 year and older) with short bowel syndrome (SBS) who are dependent on parenteral support. It is a 33-amino acid peptide identical to native human GLP-2 except for a single substitution at position 2 (glycine replaced with alanine), which confers resistance to dipeptidyl peptidase-IV (DPP-IV) cleavage and extends the half-life to approximately 2 hours — enabling once-daily subcutaneous dosing. In the pivotal STEPS trial, 63% of patients receiving teduglutide 0.05 mg/kg/day achieved a clinically meaningful 20-100% reduction in parenteral support volume at 24 weeks, compared with 30% on placebo (p=0.002). Long-term extension studies (STEPS-2 and STEPS-3) demonstrated sustained reductions in parenteral nutrition requirements over 2+ years of continuous treatment.

View full Teduglutide (Gattex/Revestive)guide →Add to schedule →

Frequently Asked Questions